Skip to main content
AI Market Summary
Loading market intelligence...

Immunomedics, Inc. (IMMU) Stock Forecast 2025 - AI Price Prediction & Analysis


Immunomedics, Inc. (IMMU) AI Stock Price Forecast & Investment Analysis

Immunomedics, Inc. Stock Price Chart and Technical Analysis

Loading Immunomedics, Inc. interactive price chart and technical analysis...

Immunomedics, Inc. (IMMU) - Comprehensive Stock Analysis & Investment Research

Deep dive into Immunomedics, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Understanding Company Overview

What this section covers: Essential business information about Immunomedics, Inc., including sector classification, industry positioning, and organizational structure.

How to interpret: Company size, sector, and employee count provide context for market position and growth potential. Leadership and founding date indicate stability and experience.

For Immunomedics, Inc.: Immunomedics, Inc. operates in the Health Technology sector, positioning it as a large-cap market leader.

Immunomedics, Inc. (Stock Symbol: IMMU) is a leading company in the Health Technology sector , specifically operating within the Biotechnology industry.

The organization employs approximately 366 professionals worldwide .

The company has established itself as a major market leader with significant institutional backing.

Understanding Financial Performance

What these metrics mean: Key financial indicators showing Immunomedics, Inc.'s revenue scale, profitability, market value, and shareholder returns.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Immunomedics, Inc.: With $20M in annual revenue and -849.1% net margin, the company demonstrates developing profitability.

Annual Revenue: $20 million generating a -849.1% net profit margin .

Market Capitalization: $18275 million - Classified as a large-cap stock with institutional-grade stability.

Return on Equity (ROE): -99.7% - Below-average shareholder return efficiency, indicating areas for operational improvement.

Understanding AI Stock Predictions

What these predictions mean: AI-powered forecasts for Immunomedics, Inc. stock using machine learning algorithms trained on historical market data and technical indicators.

How to interpret: Positive percentages indicate expected price increases, negative values suggest potential declines. Spearman correlation coefficient shows the statistical relationship between predictions and actual outcomes.

For Immunomedics, Inc.: Unlock premium access to view detailed AI predictions and price targets.

🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for Immunomedics, Inc. stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.

Understanding Market Position

What this analysis covers: Immunomedics, Inc.'s competitive positioning, market dynamics, operational efficiency, and strategic advantages within its industry.

How to evaluate: Strong cash flow generation, healthy margins, and market leadership indicate competitive advantages. Growth rates show expansion potential.

For Immunomedics, Inc.: Market positioning analysis based on available financial and operational metrics.

Immunomedics, Inc. strategically competes in the highly dynamic Biotechnology marketplace, positioning itself as a dominant large-cap market leader with significant competitive moats and institutional investor confidence .

The company maintains a healthy -643.0% gross margin, indicating strong pricing power and operational efficiency.

Immunomedics, Inc. (IMMU) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Immunomedics, Inc. stock analysis.

Loading Immunomedics, Inc. comprehensive fundamental analysis and insider trading data...

Deep dive into Immunomedics, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Immunomedics, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Immunomedics, Inc.: With a P/E ratio of -51.08, the market sees the stock as potentially undervalued.

P/E Ratio -51.08x
P/B Ratio 34.19x
Market Cap $18275M
EPS $-1.72
Book Value/Share $2.57
Revenue/Share $0.10
FCF/Share $-0.83
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Immunomedics, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Immunomedics, Inc.: An ROE of -99.7% indicates room for improvement in shareholder value creation.

ROE -99.7%
ROA -45.5%
ROIC -49.8%
Gross Margin -643.0%
Operating Margin -817.6%
Net Margin -849.1%
EBT Margin -850.3%
Tax Rate 23.2%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Immunomedics, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Immunomedics, Inc.: A current ratio of 12.84 indicates strong liquidity.

Current Ratio 12.84x
Quick Ratio 12.28x
D/E Ratio 0.47x
Financial Leverage 1.82x
Interest Coverage -6.4x
Working Capital $567M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Immunomedics, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Immunomedics, Inc.: Free cash flow of $-260M indicates cash challenges that need attention.

Operating Cash Flow $-258M
Free Cash Flow $-260M
Capital Spending $-2M
FCF/Sales -706.2%
CapEx/Sales 12.2%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Immunomedics, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Immunomedics, Inc.: An asset turnover of 0.03x suggests room for improvement in asset utilization.

Asset Turnover 0.03x
Receivables Turnover 0.9x
Inventory Turnover 12.3x
Fixed Assets Turnover 0.6x
Days Sales Outstanding 399 days
Days Inventory 30 days
Payables Period 41 days
Cash Conversion Cycle 26 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Immunomedics, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Immunomedics, Inc.: With annual revenue of $20M, Immunomedics, Inc. represents a smaller but potentially high-growth operation.

Income Statement ($ Millions)
Total Revenue $20M
Operating Income $-313M
Net Income $-353M
R&D Expense $76M
SG&A Expense $407M
Cost of Goods Sold $743M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 97%
Cash & Short-term Investments 91%
Total Liabilities 45%
Short-term Debt 2%
Accounts Receivable 2%
Inventory 2%
Dividend & Shareholder Information
Shares Outstanding 208M

Latest Immunomedics, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Immunomedics, Inc. (IMMU) stock price and investment outlook.

, source: Fox Business

After Immunomedics (NASDAQ: IMMU) shared some positive clinical data with investors, shares of the clinical-stage biotech focused on cancer rose 17% as of 3:10 p.m. EST on Wednesday. Immunomedics ...

, source: Fox Business

Immunomedics (NASDAQ: IMMU) fell 13% today, after The Fly reported that Immunomedics told an Jefferies analyst that the biotech won't report data for its cancer drug sacituzumab govitecan, which also ...

, source: Yahoo

(Reuters) - The former chief financial officer of a New Jersey biotechnology company pleaded guilty on Wednesday to insider trading, after prosecutors said he had given nonpublic information about a ...

Immunomedics, Inc. Competitors & Peer Analysis - Health Technology Sector

Comparative analysis of Immunomedics, Inc. against industry peers and competitors in the Health Technology sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio

Frequently Asked Questions - Immunomedics, Inc. Stock Forecast

How accurate are Immunomedics, Inc. stock predictions?

Our AI model shows a 8500% Spearman correlation coefficient for IMMU predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Immunomedics, Inc. stock price forecasts?

Our analysis considers Immunomedics, Inc.'s financial metrics, Health Technology sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Immunomedics, Inc. a good investment in 2025?

Based on our AI analysis, Immunomedics, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Immunomedics, Inc. forecasts updated?

Immunomedics, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want More Advanced Immunomedics, Inc. Analysis?

Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for Immunomedics, Inc. stock.

My Portfolio

Investment Dashboard

Loading your portfolio...